Program
osimertinib
Also written as “Osimertinib”, “AZD9291” and “AZD9291 tablet dosing”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Neoplasms · Renal Insufficiency · Carcinoma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 3914 open or running | phase 4since Feb 20, 2019 | Feb 25, 2013 | Feb 22, 2027phase 3 · NCT05629234 |
| Eli Lilly | 21 open or running | phase 3since Apr 3, 2015 | Apr 3, 2015 | none ahead |
| Novartis | 10 open or running | phase 3since Mar 22, 2021 | Mar 22, 2021 | none ahead |
Also a collaborator on its studies: parexel, tigermed and quintiles-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 29 studies since Feb 25, 2013.
- Apr 29, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT03944772 · 247 enrolled · United States, Denmark, Italy and more
- Apr 1, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT04351555 · 358 enrolled · United States, Austria, Brazil and more
- Sep 1, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT04606771 · 30 enrolled · United States, Argentina, India and more
- Feb 11, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT04765059 · 98 enrolled · United States, China, Germany and more
- Mar 22, 2021Novartis's first study: phase 3 study in Carcinoma, Non-Small-Cell LungNew to NovartisNovartis · NCT04816214 · 6 enrolled · Japan, Korea, Republic of, Singapore
- Nov 3, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05120349 · 390 enrolled · United States, Argentina, Brazil and more
- Nov 15, 2021Phase 2 study in Lung NeoplasmsAstraZeneca · NCT05215951 · 4 enrolled · China
- Mar 11, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05546866 · 51 enrolled · China
- Sep 1, 2022Phase 2 study in Stage II-IIIB Non-small Cell Lung CarcinomaAstraZeneca · NCT05526755 · 188 enrolled · United States, Hong Kong, Italy and more
- Nov 17, 2022Phase 3 study in NeoplasmsAstraZeneca · NCT05629234 · 37 enrolled · China, France, Japan and more
- Mar 24, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05801029 · 60 enrolled · Hong Kong, Malaysia, Singapore and more
- Dec 20, 2023Phase 2 study in Lung NeoplasmsAstraZeneca · NCT06194448 · 76 enrolled · United States, China, Israel and more
- Nov 24, 2025Phase 2 study in Lung NeoplasmsAstraZeneca · NCT07295821 · 60 planned · China
- Oct 15, 2026Primary completion moved from 2026-09-30 to 2027-01-11Date moved laterphase 3 · +3 months · NCT06417814
Ahead
- Feb 22, 2027Primary completion: phase 3 study in NeoplasmsAstraZeneca · NCT05629234
- Aug 2, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05120349
- Oct 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungAstraZeneca · NCT05801029
- May 30, 2029Primary completion: phase 2 study in Lung NeoplasmsAstraZeneca · NCT07295821
TargetBeta
“A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07295821Lung Neoplasms · China | 2 | Recruiting | AstraZeneca | May 30, 2029 | 60 |
| NCT06194448Lung Neoplasms · United States, China, Israel and more | 2 | Active, not recruiting | AstraZeneca | Jul 7, 2026 | 76 |
| NCT05801029Carcinoma, Non-Small-Cell Lung · Hong Kong, Malaysia, Singapore and more | 2 | Active, not recruiting | AstraZeneca | Oct 1, 2027 | 60 |
| NCT05629234Neoplasms · China, France, Japan and more | 3 | Active, not recruiting | AstraZeneca | Feb 22, 2027 | 37 |
| NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma · United States, Hong Kong, Italy and more | 2 | Active, not recruiting | AstraZeneca | Nov 22, 2029 | 188 |
| NCT05546866Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | AstraZeneca | Jun 30, 2029 | 51 |
| NCT05215951Lung Neoplasms · China | 2 | Terminated | AstraZeneca | Mar 9, 2023 | 4 |
| NCT05120349Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Aug 2, 2027 | 390 |
| NCT04816214Carcinoma, Non-Small-Cell Lung · Japan, Korea, Republic of, Singapore | 3 | Terminated | Novartis | Dec 27, 2022 | 6 |
| NCT04765059Carcinoma, Non-Small-Cell Lung · United States, China, Germany and more | 3 | Active, not recruiting | AstraZeneca | Oct 28, 2024 | 98 |
| NCT04606771Carcinoma, Non-Small-Cell Lung · United States, Argentina, India and more | 2 | Active, not recruiting | AstraZeneca | Dec 21, 2022 | 30 |
| NCT04351555Carcinoma, Non-Small-Cell Lung · United States, Austria, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Oct 15, 2024 | 358 |
| NCT03944772Carcinoma, Non-Small-Cell Lung · United States, Denmark, Italy and more | 2 | Active, not recruiting | AstraZeneca | May 6, 2025 | 247 |
| NCT03853551Carcinoma, Non-Small-Cell Lung · India | 4 | Completed | AstraZeneca | Apr 15, 2020 | 60 |
| NCT03521154Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Active, not recruiting | AstraZeneca | Jan 5, 2024 | 216 |
| NCT03463525Carcinoma, Non-Small-Cell Lung · Sweden | 1 | Completed | AstraZeneca | Mar 19, 2020 | 4 |
| NCT03239340Carcinoma, Non-Small-Cell Lung · United States, Italy, Korea, Republic of and more | 2 | Completed | AstraZeneca | Sep 19, 2023 | 154 |
| NCT02997501Lung Neoplasms · China | 3 | Completed | AstraZeneca | Oct 24, 2018 | 256 |
| NCT02923947Renal Insufficiency · France, Korea, Republic of, Spain | 1 | Completed | AstraZeneca | Sep 20, 2018 | 16 |
| NCT02908750Carcinoma, Non-Small-Cell Lung · France, Korea, Republic of, Spain | 1 | Completed | AstraZeneca | Jul 31, 2017 | 24 |
| NCT02789345Carcinoma, Non-Small-Cell Lung · United States, France, Korea, Republic of and more | 1 | Completed | Eli Lilly | Oct 19, 2017 | 29 |
| NCT02529995Carcinoma · China | 1 | Completed | AstraZeneca | Jan 28, 2016 | 31 |
| NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma · United States, Australia, Belgium and more | 3 | Active, not recruiting | AstraZeneca | Apr 11, 2022 | 682 |
| NCT02491944Neoplasms · United Kingdom | 1 | Completed | AstraZeneca | Aug 2015 | 27 |
| NCT02474355Lung Neoplasms · Argentina, Australia, Austria and more | 3 | Completed | AstraZeneca | Apr 18, 2019 | 3,017 |
| NCT02454933Locally Advanced or Metastatic EGFR T790M+ NSCLC · Canada, Korea, Republic of, Taiwan | 3 | Completed | AstraZeneca | Aug 21, 2017 | 29 |
| NCT02442349Carcinoma, Non-Small-Cell Lung · Australia, China, South Korea | 2 | Completed | AstraZeneca | Mar 4, 2016 | 171 |
| NCT02411448Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 3 | Active, not recruiting | Eli Lilly | Jan 23, 2019 | 545 |
| NCT02317016Carcinoma, Non-Small-Cell Lung · United States, France, Spain and more | 1 | Completed | AstraZeneca | Jul 11, 2015 | 44 |
| NCT02228369Carcinoma, Non-Small-Cell Lung · United States, Australia, Korea, Republic of and more | 1 | Completed | AstraZeneca | Aug 19, 2017 | 108 |
| NCT02224053Neoplasms · United States | 1 | Completed | AstraZeneca | Jan 2015 | 136 |
| NCT02197247Carcinoma, Non-Small-Cell Lung · United States, Korea, Republic of, Netherlands and more | 1 | Completed | AstraZeneca | Jul 9, 2015 | 41 |
| NCT02197234Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more | 1 | Completed | AstraZeneca | Apr 30, 2015 | 52 |
| NCT02179671Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | AstraZeneca | Jun 11, 2016 | 32 |
| NCT02157883Carcinoma, Non-Small-Cell Lung · United States, Belgium, Netherlands and more | 1 | Completed | AstraZeneca | Apr 3, 2015 | 39 |
| NCT02163733Carcinoma, Non-Small-Cell Lung · France, Korea, Republic of, Spain and more | 1 | Completed | AstraZeneca | Mar 24, 2015 | 38 |
| NCT02161770Neoplasms · United States, Belgium, France and more | 1 | Completed | AstraZeneca | May 16, 2017 | 30 |
| NCT02143466Advanced Non Small Cell Lung Cancer · United States, Canada, Japan and more | 1 | Active, not recruiting | AstraZeneca | Mar 4, 2020 | 344 |
| NCT02096679Healthy Volunteers · United Kingdom | 1 | Completed | AstraZeneca | Aug 2014 | 8 |
| NCT02094261Carcinoma, Non-Small-Cell Lung · United States, Canada, Hong Kong and more | 2 | Completed | AstraZeneca | May 1, 2015 | 210 |
| NCT01951599Healthy Volunteers · United States | 1 | Completed | AstraZeneca | Jun 4, 2014 | 35 |
| NCT01802632Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Completed | AstraZeneca | May 1, 2015 | 603 |
How it is read
Names in the registry
- “Osimertinib”, 14 entries
- “AZD9291”, 14 entries
- “AZD9291 tablet dosing”, 5 entries
- “AZD9291 Dosing”, 2 entries
- “Part A - AZD9291 in combination with AZD6094”, 1 entry
Codes read as this program: AZD9291.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 28 studies
- Lung Neoplasms, 5 studies
- Neoplasms, 4 studies
- Renal Insufficiency, 1 study
- Carcinoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.